Translation of Research | Business Innovation | Future of Discovery

Join us at “Accelerating Bio-Innovation 2022” - a two-day exploration of some of the key debates facing innovators of new biopharmaceuticals, from both the science and funding perspectives.

This unique, interactive and multidisciplinary summit will examine the successes and challenges in drug development including translation of cancer drugs, CAR-T therapies and PROTACs, business innovation in academia, pharma and investments and the future of drug discovery, including the role of artificial intelligence.

Featuring award-winning scientists, entrepreneurs, and business leaders including Cambridge Professors Steve Jackson, Anne Ferguson-Smith, Jason Chin, Allan Bradley, Sharon Peacock, Tony Kouzarides and Wolf Reik, Pascal Soriot (CEO, AZ), David Redfern (Chief Strategy officer, GSK), Prof Craig Crews (Yale University), Prof Tim Springer (Harvard Medical school), Debbie Baron (Head of Business Development, Pfizer), Henry Gosebruch (Chief Strategy Officer, Abbvie), Sid Mukherjee (Pulitzer Prize winner, Columbia University), Oleg Nodelman (EcoR1 Capital) and Mary Lynne Headley (Co-founder, Tesaro).

 

Pablo Legorreta Royalty Pharma Plc

Siddhartha Mukherjee Columbia University

Pascal Soriot AstraZeneca

 

 

Tim Springer Harvard University

Stephen Toope University of Cambridge

Deborah Baron Pfizer

 

 

Craig Crews Yale University

Habib Dable  Acceleron Pharma

Henry Gosebruch Abbvie

 

 

Abraham Heifets Atomwise, Inc.

Andrew Hopkins Exscientia plc

Joanna Shields BenevolentAI

 

 

Registration to the Accelerating Bio-Innovation conference is now closed. Please email [email protected] for further information.